Avoid routine high-dose escalation in ADHD
Across attention deficit hyperactivity disorder medicines, average symptom benefit often plateaus, while higher doses can increase stopping treatment due to side effects.
*Systematic review and dose–effect network meta-analysis; Level 1a (OCEBM).

Citation

Nourredine M, Jurek L, Hamza T, et al. Pharmacological interventions for ADHD: a systematic review and dose–effect network meta-analysis. Lancet Psychiatry. 2026;13:485–95.

Background

Medication dose choices for attention deficit hyperactivity disorder are often guided by limited evidence, raising concerns about both under-dosing and unnecessary dose escalation. This study estimated how benefit and tolerability change across dose ranges for multiple medicines and age groups.

Patients

People aged 5 years or older with attention deficit hyperactivity disorder in double-blind randomised controlled trials. Excluded: genetic syndromes, treatment-resistant populations, and withdrawal-phase designs.

Intervention

Oral single-drug treatment across dose ranges (stimulants and non-stimulants).

Control

Placebo and indirect comparisons across medicines within the network.

Outcome

Efficacy: change in validated symptom scales (closest to 12 weeks). Tolerability: stopping treatment due to adverse events.

Follow-up Period

Short term (about 7–8 weeks on average).

Results

113 trials were included (68 in children/adolescents; 45 in adults).
Group Medicine Approximate dose where average benefit peaked/plateaued Where stopping for side effects clearly increased
Children/adolescents Methylphenidate Up to ~45 mg/day; no added benefit at higher doses No clear dose-related increase
Children/adolescents Amphetamines Up to ~25 mg/day; no added benefit at higher doses Above ~25 mg/day
Children/adolescents Guanfacine Up to ~4 mg/day; no added benefit at higher doses Up to ~4 mg/day (median ~9.8% stopped)
Adults Amphetamines Plateau above ~50 mg/day Above ~50 mg/day
Adults Methylphenidate No clear plateau (data limited at higher doses) Above ~50 mg/day (about 7.3% stopped at 60 mg/day)

Limitations

Most data were short term, and adult fixed-dose evidence was sparse at higher doses. Race/ethnicity reporting was inconsistent. Results reflect average group effects and cannot determine the best dose for an individual patient.

Funding

National Institute for Health and Care Research (NIHR303122).

Clinical Application

Titrate upward from low doses when symptoms persist, but avoid routine dose increases beyond approved maxima, especially for stimulants, because added benefit is limited and side effects may increase.